Goldman Sachs
TGTX icon

Goldman Sachs’s TG Therapeutics TGTX Stock Holding History

Goldman Sachs’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-550,000
Closed -$18.3M – 6985
2026
Q1 		$18.3M Buy
+550,000
New +$16.4M ﹤0.01% 2519

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Goldman Sachs's TGTX Position: Q2 2026 in Review

Goldman Sachs increased its TG Therapeutics (TGTX) stake by 1.2% in Q2 2026, buying an estimated $1.09M and bringing the position to 2,314,279 shares worth $127M. The position accounts for 0.01% of the portfolio, ranked #1052.

Goldman Sachs first reported a position in TGTX in Q2 2013 and has held it in 43 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Goldman Sachs held 2,314,279 shares of TG Therapeutics worth $127M as of Q2 2026.
  • Goldman Sachs bought 26,591 TG Therapeutics shares in Q2 2026, an estimated $1.09M.
  • TG Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1052 holding.
  • Goldman Sachs first reported a position in TG Therapeutics in Q2 2013 and has held it in 43 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.